Brand-Name vs. Compounded GLP-1:
What's the Real Price Difference?

How to Use This Calculator

The Brand vs. Compounded Savings Calculator gives you a side-by-side financial comparison of your current brand-name GLP-1 drug against the compounded equivalent — with a safety assessment built in. Most cost comparison articles give you a generic number. This calculator uses your actual costs so the savings figure reflects your real situation, not an average.

Question 1 asks which brand-name drug you are taking or considering. This determines the compounded equivalent shown — Wegovy and Ozempic both use semaglutide as the active ingredient, while Mounjaro and Zepbound both use tirzepatide. Select the brand name on your prescription even if you are exploring the compounded option for the first time.

Question 2 is the most important input. Enter what you actually pay per month, not the list price. If you pay a $25 insurance copay, enter $25. If you use the NovoCare savings program and pay $349, enter $349. If you pay full list price with no discount, enter your actual pharmacy charge. For the compounded side, enter the monthly price you have been quoted by a telehealth platform or compounding pharmacy. If you have not been quoted a price yet, use one of the quick-pick preset buttons — $99, $149, or $299 represent the three most common compounded semaglutide pricing tiers in 2026.

Question 3 asks about pharmacy accreditation. This is not a formality — it directly affects the safety section of your results and flags specific verification steps if you have not yet confirmed your pharmacy's registration status. Question 4 captures your reason for comparing, which tailors the insight and recommendation shown after calculation.

Understanding Your Results

The large green number at the top of your results is your estimated annual savings from switching to compounded. Below it, the side-by-side cards show your current brand-name monthly and annual spend next to the compounded equivalent, making the dollar gap immediately visible. The savings breakdown table underneath shows monthly savings, annual savings, and a five-year projection — because GLP-1 treatment is typically long-term, and small monthly differences compound into significant lifetime figures.

The safety assessment section

This section is unique to this calculator and reflects the most important consideration in the brand-versus-compounded decision: it is not only about price. The safety assessment is generated based on your accreditation answer in Question 3. If you confirmed a 503B registration, the assessment notes that 503B pharmacies operate under FDA oversight comparable to traditional drug manufacturers and represent the lowest-risk compounded option. If you selected 503A registered, the assessment notes that 503A pharmacies are FDA-registered for patient-specific compounding and are generally considered safe when operating in compliance with state board requirements, though quality controls are less rigorous than 503B facilities. If you selected "Not yet checked" or "Not sure," the assessment provides specific steps for verifying your pharmacy's status before you place an order, including how to search the FDA's list of registered compounders and what to ask your telehealth provider.

What Is Compounded Semaglutide and Tirzepatide?

Compounded semaglutide and tirzepatide are versions of the same active ingredients found in Ozempic, Wegovy, Mounjaro, and Zepbound — manufactured by compounding pharmacies rather than by Novo Nordisk or Eli Lilly. Compounding pharmacies can legally produce these formulations when they differ meaningfully from the commercially available version, for example in dose strength, concentration, or additional ingredients such as vitamin B12.

The FDA resolved the official shortage designations for semaglutide and tirzepatide in early 2025, which changed the legal landscape for compounding. Under current rules, 503A pharmacies can still produce non-copy GLP-1 formulations for individual patients with a valid prescription when there is documented clinical rationale for why the commercial product does not meet the patient's needs. 503B outsourcing facilities operate under different rules and may continue producing certain formulations. The rules in this area continue to evolve — verify the current status of your pharmacy's specific product with your prescriber and the pharmacy directly.

What to Do Based on Your Results

If the savings are under $100 per month

A difference of under $100 per month may not justify switching from brand-name to compounded, particularly if you have insurance coverage or a manufacturer savings card that brings your brand cost down to $25 to $100. The quality assurance and regulatory oversight of an FDA-approved brand-name drug has real value, and when the price gap is small, most clinicians and patients choose to stay with the brand. Consider instead whether you are fully using all available brand savings programs — our True Monthly Cost Calculator shows every scenario including manufacturer programs you may not know about.

If the savings are $200 or more per month

A savings of $200 or more per month — $2,400 or more per year — is financially significant for most patients and worth serious consideration. At this level, the savings over two or three years of treatment represent a meaningful sum. The key steps are: verify your pharmacy's accreditation status using the FDA's online database of registered compounders, confirm with your prescriber that the compounded formulation is clinically appropriate for your specific dose and situation, and request a certificate of analysis for the first batch you receive. If your compounded price is in the $99 to $149 range versus a brand list price near $1,000 or more, the financial case for switching is among the strongest available in any prescription drug category.

If you are already on compounded and considering switching to brand

Switching from compounded to brand-name is straightforward from a clinical standpoint — there is no washout period required when switching between semaglutide formulations, though your prescriber may adjust your starting dose on the brand product. The primary reason patients switch back is the end of the FDA shortage designation, which changed the regulatory standing of compounded GLP-1s and led some patients to prefer the additional certainty of an FDA-approved product. Use this calculator in reverse — enter the compounded cost in the brand column and the brand cost in the compounded column — to see the monthly premium you would pay for brand-name certainty.

To complete your cost picture, use our HSA/FSA Tax Savings Calculator to apply a pre-tax discount on top of whatever option you choose, and our True Monthly Cost Calculator to see all four payment scenarios simultaneously.

Sources: FDA compounding guidance and 503A/503B pharmacy registration database (fda.gov), Novo Nordisk NovoCare program pricing, Eli Lilly LillyDirect pricing, FDA semaglutide and tirzepatide shortage resolution notices (2025), PCAB pharmacy accreditation program. All pricing estimates current as of May 2026. Compounding rules are subject to regulatory change — verify current status with your prescriber and pharmacy. This content is for informational purposes only and does not constitute medical or financial advice.